News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

EHR Sales Reached $31.5 Billion in 2018 Despite Concerns over Usability, Interoperability, and Ties to Medical Errors

Cerner and Epic are the industry’s revenue leaders, though smaller vendors remain popular with physician groups

Sales of electronic health record (EHR) systems and related hardware and services reached $31.5 billion in 2018. And those sales will increase, according to a 2019 market analysis from Kalorama Information. This is important information for clinical laboratories and anatomic pathology groups that must interface with the EHRs of their physician clients to enable electronic transmission of lab orders and test results between doctor and lab.

The Kalorama report, titled, “EMR 2019: The Market for Electronic Medical Records,” ranks EHR companies based on revenue rather than market penetration. Kansas City-based Cerner holds the No.1 spot on the list. That may be due to Cerner’s securing one of the largest IT contracts in the federal government—a potential $10 billion deal over 10 years with the U.S. Department of Veterans Affairs (VA) to replace the VA’s VistA medical record system.

Is Bigger Better?

Kalorama’s ranking includes familiar big EHR manufacturer names—Cerner (NASDAQ:CERN) and Epic—and includes a new name, Change Healthcare, which was born out of Change Healthcare Holding’s merger with McKesson. However, smaller EHR vendors remain popular with many independent physicians.

“We estimate that 40% of the market is not in the top 15 [in total revenue rankings],” said Bruce Carlson, Kalorama’s publisher, in an exclusive interview with Dark Daily. “There’s a lot of room. There are small vendors out there—Amazing Charts, e-MDs, Greenway, NextGen, Athena Health—that show up on a lot of physician surveys.”

“The EHR is really important,” noted Bruce Carlson (above), Publisher at Kalorama. “Since there are a variety of systems—sometimes different from the LIS [laboratory information management system]—you want to make sure you know the vendors and the space.” Carlson says opportunities remain for new entrants in the 700-plus competitor space, which is expected to see continued mergers and acquisitions that will affect clinical laboratories and their client physicians. (Photo copyright: Twitter.)

Interoperability a Key Challenge, as Most Medical Laboratories Know

Interoperability—or the lack thereof—remains one of the industry’s biggest challenges. For pathologists, that means seamless electronic communication between medical laboratories and provider hospitals can be elusive and can create a backlash against EHR vendors.

Kalorama notes a joint investigation by Fortune and Kaiser Health News (KHN), titled, “Death by a Thousand Clicks: Where Electronic Health Records Went Wrong.” The report details the growing number of medical errors tied to EHRs. One instance involved a California lawyer with herpes encephalitis who allegedly suffered irreversible brain damage due to a treatment delay caused by the failure of a critical lab test order to reach the hospital laboratory. The order was typed into the EHR, but the hospital’s software did not fully interface with the clinical laboratory’s software, so the lab did not receive the order.

“Many software vendors and LIS systems were in use prior to the real launching of EHRs—the [federal government] stimulus programs,” Carlson told Dark Daily. “There are a lot of legacy systems that aren’t compatible and don’t feed right into the EHR. It’s a work in progress.”

Though true interoperability isn’t on the immediate horizon, Carlson expects its arrival within the next five years as the U.S. Department of Health and Human Services ramps up pressure on vendors.

“I think it is going to be a simple matter eventually,” he said. “There’s going to be much more pressure from the federal government on this. They want patients to have access to their medical records. They want one record. That’s not going to happen without interoperability.”

Other common criticisms of EHRs include:

  • Wasted provider time: a recent study published in JAMA Internal Medicine notes providers now spend more time in indirect patient care than interacting with patients.
  • Physician burnout: EHRs have been shown to increase physician stress and burnout.
  • Not worth the trouble: The debate continues over whether EHRs are improving the quality of care.
  • Negative patient outcomes: Fortune’s investigation outlines patient safety risks tied to software glitches, user errors, or other flaws.

There’s No Going Back

Regardless of the challenges—and potential dangers—it appears EHRs are here to stay. “Any vendor resistance of a spirited nature is gone. Everyone is part of the CommonWell Health Alliance now,” noted Carlson.

Clinical laboratories and pathology groups should expect hospitals and health networks to continue moving forward with expansion of their EHRs and LIS integrations.

“Despite the intensity of attacks on EHRs, very few health systems are going back to paper,” Carlson said in a news release. “Hospital EHR systems are largely in place, and upgrades, consulting, and vendor switches will fuel the market.”

Thus, it behooves clinical laboratory managers and stakeholders to anticipate increased demand for interfaces to hospital-based healthcare providers, and even off-site medical settings, such as urgent care centers and retail health clinics.

—Andrea Downing Peck

Related Information:

EMR 2019

EMR Market Tops $30 Billion, Despite Intensifying Criticism and Challenges

VA-Cerner $10B EHR Control Finally Gets Signed

McKesson and Change Healthcare Announce New Company Will be Named Change Healthcare

Assessment of Inpatient Time Allocation among First-Year Internal Medicine Students Using Time-Motion Observation

Kalorama Report Analyzes Global EMR/EHR Market as Tech Giants Apple, Google, and Microsoft Prepare to Launch Their Own Offerings. Will This Alter Current Conditions for Clinical Laboratories and Pathologists?

Ohio State University Scientists Discover Nearly 200,000 Unknown Viruses in Ocean Depths; Could Lead to Biotechnology Breakthroughs

Pole-to-pole sampling of marine life leads researchers to conclude the world’s oceans could hold the key to many scientific and biotechnological advancements

Virologists and microbiologists will be intrigued to learn that scientists at Ohio State University (OSU) have identified nearly 200,000 previously unknown viruses living deep in the oceans. The catalog of 195,728 viruses could serve as a “road map” to a better understanding of ecosystems within the world’s oceans and the role they play in maintaining the health of the planet.

Though the research was not specifically directed at developing useful insights for clinical care, it could one day lead to new diagnostic assays or therapies. For clinical laboratories and anatomic pathology groups, this study demonstrates how understanding and knowledge about viruses and other organisms continue to grow.

The researches published their findings in the journal Cell

Viruses Are Tiny but Important

The OSU researchers led a 24-member team’s effort to expand the catalog of ocean viruses and draw the first global map of viral diversity.

“Viruses tend to steal genes and do really interesting things with them. So, someone who’s savvy in biotechnology can mine this data set to find new enzymes that can help us in our everyday lives, whether that’s cosmetic products or creating a new thermocycler or some sort of engineering process,” Matthew Sullivan, PhD, a microbiologist at OSU and one of the study’s authors, told CNN.

“Viruses are these tiny things that you can’t even see, but because they’re present in such huge numbers, they really matter,” Matthew Sullivan, PhD, a microbiologist at Ohio State University and one of the study’s authors, said in a new release. “We’ve developed a distribution map that is foundational for anyone who wants to study how viruses manipulate the ecosystem. There were many things that surprised us about our findings.” These new discoveries could someday form the basis for new medical laboratory tests and therapeutic drugs. (Photo copyright: Ohio State University.)

According to the news release, “The samples were collected during the unprecedented three-year Tara Oceans Expedition, in which a team of more than 200 experts took to the sea to catalog and better understand the unseen inhabitants of the ocean, from tiny animals to viruses and bacteria.”

“What was really exciting was now being able to study these viruses at two important levels—the population level and by looking at genetic variation within each population, which tells us about evolution,” Ann Gregory, PhD, co-lead author of the study, said in an OSU news release. “We have expanded the number of known viral populations more than tenfold and this new map will help us understand the impact of ocean viruses on a global level,” she added.

A news release from Tara Ocean Foundation notes that prior ocean surveys had identified 16,000 viral species.

Massive Quest for Knowledge

The OSU scientists studied ocean life from varying ocean depths, stretching from pole to pole, using samples collected during the Tara Oceans expeditions, which took place from 2009-2013. The Tara Ocean Foundation has backed 11 scientific expeditions and collected more than 60,000 samples that have been the basis for more than 70 scientific publications.

The team of researchers split the viruses into five ecological zones: all depths of the Arctic and Antarctic and three distinct depths of the Temperate and Tropical regions, noted the OSU study.

By developing new methods to sequence viruses in planktonic populations, the OSU research team, according to the Tara Ocean press release, was able to understand genetic variations:

  • Between individuals within each population;
  • Between populations within each viral community; and
  • Between communities across several environments of the global oceans, as well as study the driving forces behind all these variations.

In its news release, Tara Ocean Foundation pointed out one surprise was the “cradle of viral diversity” found in the Arctic Ocean, which had not been part of earlier studies of ocean life.

“This research has significant implications for understanding how ocean micro-organisms affect the atmosphere,” Sullivan said in the Cell Press news release, which goes on to note that, “The investigators say that having a more complete picture of marine viral distribution and abundance will help them to determine which viruses they should be focusing on for further studies.”

“Previous ocean ecosystem models have commonly ignored microbes, and rarely included viruses, but we now know they are a vital component to include,” said Sullivan.

At this time, the OSU study offers little that clinical laboratories can use other than a deeper awareness of how viruses impact our world and environment. However, further study of the ocean depths may yield surprises that also expand medical knowledge and lead to new therapies and diagnostic tests.

—Andrea Downing Peck

Related Information:

The World’s Oceans Have Nearly 200,000 Viral Species–about 12 Times More than Previously Known

Researchers Detail Marine Viruses from Pole to Pole

Marine DNA Viral Macro- and Micro-Diversity from Pole to Pole

The Arctic Ocean, Cradle of Viral Biodiversity

Pole-to-Pole Study of Ocean Life Identifies 200,000 Marine Viruses

Microbial Surveillance Study Snares Patients Entering Michigan Hospitals with Drug-Resistant Bacteria on Their Hands

Thorough hand-washing protocols aren’t just for healthcare professionals anymore. Patients also need to be educated to prevent hospital-acquired infections

Microbiologists and clinical laboratory managers will be particularly interested to learn that patients are bringing deadly organisms into hospitals on their hands. That’s the conclusion of a University of Michigan (UM) study which found that as patients enter and move throughout hospitals, they deposit and spread multi-drug resistant organisms, or MDROs on clinical surfaces. When those surfaces are not properly decontaminated, the bacterial contamination spreads on contact.

This finding has implications for the nosocomial infection teams in hospitals that include microbiologists and clinical laboratories. After all, every day there is a large flow of walk-in patients and visitors who come in contact with dozens of surfaces. The potential for contamination with multi-drug resistant organisms is high.

Antibiotic-resistant bacteria have been the root cause of a marked increase in hospital-acquired infections (HAIs), which Dark Daily has covered extensively. That’s why healthcare professionals practice proper hand-washing protocols to help reduce the transmission of pathogens and curtail possible infections.

The UM study, however, suggests that patients also should be educated on proper hand hygiene to diminish the potential spread of bacteria, especially before making trips to the emergency room.

The UM researchers published their study in the Oxford Academic journal Clinical Infectious Diseases.

How to Kill a Superbug

Between February and July of 2017, UM researchers at two hospitals in Southeast Michigan tested 399 general medicine hospital patients for the presence of MDROs, also known as superbugs. They swabbed the palms, fingers, and around the nails of the patients’ dominant hands and the interior of both nostrils.

The researchers found that 14% of the patients tested positive for MDROs. In addition, nearly one third of high-touch objects and surfaces in the hospital rooms tested positive for superbugs as well.  

The hospital room surfaces that were swabbed for the presence of MDROs were:

  • Bed control/bed rail;
  • Call button/television remote;
  • Bedside tray table top;
  • Telephone;
  • Toilet seat; and
  • Bathroom door knob.

The research team specifically looked for:

Due to the overuse of antibiotics, these types of bacteria are often resistant to the drugs that were once used to kill them.

“Hand hygiene narrative has largely focused on physicians, nurses, and other frontline staff, and all the policies and performance measurements have centered on them, and rightfully so,” said Lona Mody, MD (above) in a press release. Mody is Professor of Internal Medicine at UM and one of the lead researchers for the study. “But our findings make an argument for addressing transmission of MDROs in a way that involves patients, too.”

Anatomy of a Hospital-Acquired Infection

The scientists tested patients and surfaces at different stages of their hospital stays. The samples were taken on the day of admission, days three and seven of the stays, and weekly thereafter until the patients were discharged.

The team found that 6% of the patients who did not have MDROs present at the beginning of their hospital stays tested positive for superbugs at later stages of their stays. Additionally, 20% of the tested objects and surfaces in the patients’ rooms had superbugs on them at later test stages that were not present earlier in the hospital stays.

“This study highlights the importance of hand washing and environmental cleaning, especially within a healthcare setting where patients’ immune systems are compromised,” noted Katherine Reyes, MD, Department of Infectious Diseases, Henry Ford Hospital, in the press release. “This step is crucial not only for healthcare providers, but also for patients and their families. Germs are on our hands; you do not need to see to believe it. And they travel. When these germs are not washed off, they pass easily from person to person and objects to person and make people sick.”

Patients included in the study had to be new admissions, on general medicine floors, and at least 18 years of age. Criteria that excluded individuals from participation in the research included:

  • Being in observation status, typically after a medical procedure;
  • Transfers from other hospitals;
  • Transfers from intensive care units;
  • Having cystic fibrosis (these patients have a higher likelihood of MDRO colonization);
  • Receiving end-of-life care; and
  • Non-English speaking.

Patients who were transferred to a room on a nonparticipating floor within the hospitals were immediately discharged from the study. 

Patients Travel Throughout Hospitals Spreading Germs

The presence of superbugs on patients or surfaces does not automatically translate to a patient getting sick with antibiotic-resistant bacteria. Only six of the patients in this study developed MRSA. However, all six of those individuals tested positive for the superbug either on their hands or on surfaces within their room. 

The researchers noted that hospital patients typically do not stay in their rooms. They are encouraged to walk throughout the hospital to speed up the recovery process, and often are transported to other areas of hospitals for medical tests and procedures. Patients also may be picking up superbugs from other patients and staff members, other hospital areas, and commonly-touched surfaces.

The UM researchers concluded in their study that “while the burden of preventing infections has largely been borne by [healthcare personnel], our study shows that patient hands are an important reservoir and play a crucial role in the transmission of pathogens in acute care hospitals. Thus, patient hand hygiene protocols should be implemented and tested for their ability to reduce environmental contamination, pathogen transmission, and healthcare-associated infections, as well as to increase meaningful patient engagement in infection prevention.”

“Infection prevention is everybody’s business,” stated Mody in the press release. “We are all in this together. No matter where you are, in a healthcare environment or not, this study is a good reminder to clean your hands often, using good techniques—especially before and after preparing food, before eating food, after using a toilet, and before and after caring for someone who is sick—to protect yourself and others.”

These research findings should prove to be valuable for infection control teams and microbiology laboratories in the nation’s hospitals and health systems, as well as independent clinical laboratories, urgent care centers, and retail healthcare clinics.

Learning more about the transmission of infectious agents from patient to patient and from surfaces to patients could aid in the development of new techniques and strategies to prevent superbugs from manifesting in medical environments.

—JP Schlingman

Related Information:

‘Superbugs’ Found on Many Hospital Patients’ Hands and What They Touch Most Often

Multidrug-resistant Organisms in Hospitals: What Is on Patient Hands and in Their Rooms?

Unexpected Discovery of Source of Lethal, Antibiotic-Resistant Strain of E. Coli Could Lead to New Medical Laboratory Tests and Preventative Treatment

Lurking Below: NIH Study Reveals Surprising New Source of Antibiotic Resistance That Will Interest Microbiologists and Medical Laboratory Scientists

Pathologists and Clinical Laboratories to Play Critical Role in Developing New Tools to Fight Antibiotic ResistanceCould Proximity of Toilets to Sinks in Medical Intensive Care Units Contribute to Hospital-Acquired Infections?

Researchers at Princeton University Develop Tiny Biosensor Chip That Can Be Manufactured Cheaply and Possibly Perform Diagnostics Inside the Human Body

Miniaturization of clinical laboratory testing continues to intrigue pathology researchers, medical scientists, and diagnostics developers who see the technology as a way to bring pathology diagnostics to resource deficient areas

Can useful, fast, and cheap medical laboratory tests be performed using the million-pixel cameras found in today’s smartphones, in combination with microchips and other technologies? A team of researchers at Princeton University believe they are on the path to achieving those goals.

Dark Daily has covered the development of “lab-on-a-chip” miniature diagnostic technologies for many years. Through these diminutive devices, clinical laboratory testing has been brought to remote regions of the world where even basic resources like electricity and adequate clean water are in short supply.

The Princeton researchers are developing their own tiny biosensor microchip. The device reads fluorescent light and could, they say, be used to diagnose disease from inside the human body.

The researchers published their findings in ACS Photonics, a journal of the American Chemical Society (ACS), and Biomedical Optics Express, an online journal published by The Optical Society. Both peer-reviewed scientific journals specialize in the fields of photonics and optics.

Revolutionary Use of Standard Microchip Technology

The device developed by the Princeton University researchers uses silicon chip technology to perform various types of clinical laboratory assays.

“The key idea is to allow complex optical systems in modern-day chips,” said Kaushik Sengupta, PhD, Assistant Professor of Electrical Engineering at Princeton and one of the project leaders, in a press release. “All smartphones carry a million-pixel camera. How do we turn this into a device that allows laboratory-quality diagnostics?”

The miniature device (above) uses standard microchip technology consisting of tiny metal layers. It’s those layers that serve as the biosensor. The chip measures a mere four millimeters (approximately 5/32 of an inch) per side, and according to the University of Princeton scientists, it can be mass produced in a cost-effective manner using standard manufacturing techniques and does not require detailed assembly. (Photo copyright: Lingyu Hong/University of Princeton.)

The researchers discovered that existing microchip technology can be adapted to “take advantage of light’s unusual behavior when interacting with structures smaller than wavelength of light,” the press release noted. 

“We show these complex optical biosensor systems can also be realized in the same technology with absolutely no change in manufacturing the microchip,” Sengupta said.

Employing existing manufacturing would make mass producing the chips highly cost effective compared to other lab-on-a-chip technologies. And, if the diagnostics are accurate as well, clinical laboratories could have a remarkable new tool to aid physicians in the diagnosis of disease.

How It Works

The Princeton scientists say light harnessed by the fluorescence-based biosensor can detect and differentiate biological substances ranging from bacterial Deoxyribonucleic acid (DNA) to hormones present in humans.

They also claim their sensor can detect tiny molecules, such as DNA and proteins, in liquid samples as small as one microliter. By comparison, a single drop of water holds about 50 microliters. The researchers say the sensitivity of their microchip in analyzing this tiny sample is comparable to results achieve by diagnostic laboratories.

“We show for the first time that this level of optical field manipulation is possible in a silicon chip. By eliminating all classical optics, the system is now small enough that you could start thinking about putting it in a pill,” said Kaushik Sengupta, PhD, Assistant Professor of Electrical Engineering at Princeton. He’s shown above with Haw Yang, PhD (on right), Professor of Chemistry and Principle Investigator at the Haw Yang Laboratory at Princeton University. “You could start thinking about diagnostics inside the body in a way you could not think about before,” Sengupta concluded. (Photo copyright: Frank Wojciechowski/Princeton University.)

Like a traditional lab setup, the chip uses chemical antibodies to target certain molecules. These antibodies are then altered to propagate a specific light wavelength when they are exposed to a distinct molecule. Exposure to ultraviolet light causes the antibodies to glow a faint red color when they come into contact with the targeted substance.

Cheaper Diagnostics for the Developing World

The researchers hope that their miniature chip will someday be used as a mainstream diagnostic technology, and that it may lead to the development of other, similar diagnostic products. 

“Once we make the diagnostics cheaper, we can enable diagnostics in the developing world,” stated Sengupta. “And it’s not just diagnostics. What we have come up with here is just a low-cost, tiny fluorescent sensor and you can use fluorescent sensing in many different things: for food and water-quality monitoring, environmental monitoring, and industrial applications.”

More research is required to ensure the effectiveness of the new technology. And it will need to receive clearance from the federal Food and Drug Administration (FDA) before going into widespread production. Nevertheless, this newest miniature lab-on-a-chip technology could prove beneficial to clinical laboratories in the future, as a cost-effective tool to diagnose disease and better serve medical professionals and patients in resource-strapped regions of the world. 

—JP Schlingman

Related Information:

New Technology Marks Key Step Toward Shrinking a Medical Lab to Fit on Fingertip

Integrated Angle-Insensitive Nanoplasmonic Filters for Ultraminiaturized Fluorescence Microarray in a 65 nm Digital CMOS Process

Nano-plasmonics and Electronics Co-integration in CMOS Enabling a Pill-sized Multiplexed Fluorescence Microarray System

Lab-on-a-Fiber Technology Continues to Highlight Nano-Scale Clinical Laboratory Diagnostic Testing in Point-of-Care Environments

IBM and Mount Sinai Researchers Develop Innovative Medical Lab-on-a-Chip Solution

Lab-on-a-Chip Diagnostics: When Will Clinical Laboratories See the Revolution?

Sleek ‘Lab in a Needle’ Is an All-in-One Device That Detects Liver Toxicity in Minutes during a Study, Showing Potential to Supplant Some Medical Laboratory Tests

Implantable Medical Laboratory-on-a-Chip Continuously Monitors Key Chemicals in Chemotherapy and High-Risk Patients

UPS and WakeMed Now Use Aerial Drone for Daily Transport of Clinical Laboratory Specimens; In Australia, Google Wing Initiates Drone Delivery Service

Drone delivery of goods, including medical laboratory specimens, gains popularity around the world and FAA licensing in the US

In April, Dark Daily’s sister publication The Dark Report was first to report WakeMed Health and Hospitals’ use of a quadcopter drone to deliver patients’ medical laboratory specimens. The drone flew roundtrip between a complex of physicians’ offices on WakeMed’s Raleigh, N.C. campus and the central clinical laboratory.

The flight was the culmination of a multi-year drone-delivery pilot program during which a team at WakeMed collaborated with the United Parcel Service (UPS), the Federal Aviation Commission (FAA), and the North Carolina Department of Transportation (NCDOT). Matternet of Menlo Park, Calif., manufactured the drones used for the flights.

The April flight was the first time a drone transport of medical laboratory specimens in the US generated revenue.

Google Drone Delivery?

Not to be outdone, Alphabet (NASDAQ:GOOG), Google’s parent company, appears to be getting in on the trend. In April, the FAA issued an Air Carrier Certification to Wing Aviation LLC, an air delivery developer and subsidiary of Alphabet. Wing has recently launched a drone delivery service in Canberra, Australia and is testing a similar drone delivery service in the US.

“Our service allows customers to order a range of items such as fresh food, hot coffee, or over-the-counter chemist items on our mobile app, and have them delivered directly to their homes by drone in minutes,” Wing stated in a press release.

The photo above shows a Virginia family receiving breakfast delivered by a Wing drone, part of an FAA validation flight. (Photo copyright: Wing Aviation.)

The FAA’s Air Carrier Certification allows Wing to deliver goods from local businesses to private homes in the US. Their vertical take-off drones weigh about 11 pounds, are equipped with a hover propeller to reduce noise, and have wings that allow the devices to fly further and faster while using less energy.

The FAA certification restricts drone deliveries to daylight hours only with no flying in the rain. The devices are allowed to fly over people but cannot hover above them, nor can they carry any hazardous materials.  

The company plans to launch a trial delivery service later this year in the Blacksburg and Christiansburg areas of Southwest Virginia. Wing hopes to add other markets to its drone delivery service in the future. 

“This is an important step forward for the safe testing and integration of drones into our economy. Safety continues to be our number one priority as this technology continues to develop and realize its full potential,” said U.S. Secretary of Transportation, Elaine L. Chao, in a press release.

Wing Drones Deliver Over Australia Too!

Wing has been testing its drone delivery service in Australia since 2014. Over the past 18 months, Wing has flown over 70,000 test flights and made more than 3,000 successful deliveries—including food, small household items, and over-the-counter drug store items—as part of the Australia project.

In April, the company launched a commercial air delivery service in the North Canberra area of Australia after receiving approval from the Civil Aviation Safety Authority (CASA).

Drone Delivery Could Reshape Healthcare

Unmanned aerial vehicles (UAVs, but commonly called drones) continue to gain in popularity around the world. As more drones appear in the sky, more practical functions are being discovered for them, including medical uses.

According to an article penned by Jeremy Tucker, DO, for Drones in Healthcare, numerous potential medical uses exist for drones. In addition to transport and delivery services, they may also be helpful in search and rescue missions and providing medical care and telemedicine services. Tucker is Executive Director for Patient Safety Solutions at US Acute Care Solutions.

“Drones are going to decrease the reliance on human beings that provide care and decrease the cost of assisting people,” he predicted. “Being able to cross long distances at faster speeds to deliver blood products and lab samples also is a huge benefit. Now transporting blood products between hospitals, for example, involves vehicles on the ground that are prone to accidents and delays. Drones can help decrease those incidents.”

Prior to using drones for clinical laboratory specimen deliveries, WakeMed relied on courier cars and trucks to transport specimens within the campus. The ground delivery service could take up to an hour to complete. By comparison, drones can make the same delivery in minutes, ensuring lab specimens remain viable, and getting test results to patients faster.

Drone Delivery Around the World!

Dark Daily previously covered the use of drones to deliver laboratory specimens in Switzerland and laboratory supplies and blood products in Rwanda. And in 2017, Dark Daily reported that a team of researchers from Johns Hopkins University had successfully flown a drone carrying lab specimens more than 161 miles across the Arizona desert. 

Might we soon see a Google drone delivery service for clinical laboratory specimens as well?

The utilization of drones represents another market trend that is creating opportunities for clinical laboratories. Using drones to transport lab specimens could be a potential source of revenue and presents labs with a pathway for providing value-added, timely service to healthcare networks.

—JP Schlingman

Related Information:

Google’s Wing Kicks off First Drone Delivery Service in Australia

UPS Partners with Matternet to Transport Medical Samples via Drone Across Hospital System in Raleigh, N.C.

Matternet Partners with UPS as It Launches First Regular Drone Delivery Service in U.S.

UPS Launches First Revenue Drone Delivery Service in U.S.

FAA and NCDOT Launch Drone Pilot Over WakeMed

UAS Integration Pilot Program

NCDOT Launches ‘First Flight’ in Drone Pilot Program

Chairman and CEO David Abney Explains UPS’ Drive Toward Drone Technology

WakeMed Used Drone to Deliver Patient Specimens

Drones Used to Deliver Clinical Laboratory Specimens in Switzerland

;